Cargando…

Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma

Intermediate-stage hepatocellular carcinoma (HCC) consists of heterogeneous groups of patients in terms of tumor burden and organ function reserves. Although liver-directed therapy (LDT), including trans-catheter arterial chemoembolization, radiofrequency ablation or even surgical resection, is the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Yung-Yeh, Liu, Yi-Sheng, Hsiao, Chin-Fu, Hsu, Chiun, Chen, Li-Tzong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170176/ https://www.ncbi.nlm.nih.gov/pubmed/35677350 http://dx.doi.org/10.2147/JHC.S220978

Ejemplares similares

DNA Methylation Biomarkers as Prediction Tools for Therapeutic Response and Prognosis in Intermediate-Stage Hepatocellular Carcinoma
por: Lu, Chang-Yi, et al.
Publicado: (2023)

Management of patients with intermediate stage hepatocellular carcinoma
por: Prince, David, et al.
Publicado: (2020)

Intermediate stage hepatocellular carcinoma: a summary review
por: Elshaarawy, Omar, et al.
Publicado: (2019)

Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
por: Torimura, Takuji, et al.
Publicado: (2021)

Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis
por: Lin, Chih-Wen, et al.
Publicado: (2020)

Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma
por: Shao, Yu-Yun, et al.
Publicado: (2021)

Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma
por: Hsu, Wei-Fan, et al.
Publicado: (2021)

Liver resection versus transarterial chemoembolization for the treatment of intermediate‐stage hepatocellular carcinoma
por: Chen, Shuling, et al.
Publicado: (2019)

Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
por: Zhuang, Lei, et al.
Publicado: (2017)

Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
por: Roth, Gaël Stéphane, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
por: Zhou, Qunfang, et al.
Publicado: (2020)

Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification
por: Yamamoto, Masateru, et al.
Publicado: (2021)

New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma
por: Osanto, Susanne, et al.
Publicado: (2022)

Radiofrequency Ablation Is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size
por: Lin, Zhong-Zhe, et al.
Publicado: (2013)

Predicting the Initial Treatment Response to Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma by the Integration of Radiomics and Deep Learning
por: Peng, Jie, et al.
Publicado: (2021)

Living donor liver transplantation for Barcelona clinic liver cancer (BCLC) intermediate-stage hepatocellular carcinoma
por: Tsai, Ming Chao, et al.
Publicado: (2022)

Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma
por: Kim, Jun Young, et al.
Publicado: (2016)

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2020)

The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma
por: Kaibori, Masaki, et al.
Publicado: (2021)

Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
por: Zhang, Menglong, et al.
Publicado: (2022)

Postoperative outcomes and recurrence patterns of intermediate-stage hepatocellular carcinoma dictated by the sum of tumor size and number
por: Hu, Xin-Sheng, et al.
Publicado: (2022)

Evolution and current status of the subclassification of intermediate hepatocellular carcinoma
por: Yi, Peng-Sheng, et al.
Publicado: (2020)

Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma
por: Tian, Meng-Xin, et al.
Publicado: (2019)

Safety and effectiveness of new embolization microspheres SCBRM for intermediate-stage hepatocellular carcinoma: A feasibility study
por: Liu, Yi-Sheng, et al.
Publicado: (2021)

A Prognostic Score for Patients with Intermediate-Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
por: Ogasawara, Sadahisa, et al.
Publicado: (2015)

Latent Class Analysis of Subphenotypes in Intermediate-Stage Hepatocellular Carcinoma after Transarterial Chemoembolization
por: Chen, Siyu, et al.
Publicado: (2022)

Retracted: Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
por: Markers, Disease
Publicado: (2023)

Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma
por: Hsiao, Pojen, et al.
Publicado: (2019)

Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection
por: Chi, Chen-Ta, et al.
Publicado: (2021)

Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
por: Yeo, Winnie, et al.
Publicado: (2010)

Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models
por: Zhang, Yong-Fa, et al.
Publicado: (2021)

Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies
por: Liu, Yu-Chin, et al.
Publicado: (2020)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2021)

Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients
por: Nishikawa, Hiroki, et al.
Publicado: (2014)

Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making
por: Zhang, Yong-Fa, et al.
Publicado: (2016)

Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma
por: Liu, Furong, et al.
Publicado: (2019)

Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study
por: Lu, Linbin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rcaomqu287vdd1l9o4r2k93sks